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Introduction 
Gastric cancer (GC) is the fourth commonest type of cancer 
and despite great improvements in treatment regimes, it 
still carries the second highest mortality rate for cancer 
worldwide (1,2). Over 90% of GC are adenocarcinomas, 
proximal (arising from the cardia) and distal (non-
cardia tumours) with two main histological types: (I) well 
differentiated/ intestinal type, or (II) undifferentiated/
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Background: Gastric cancer (GC) is the fourth commonest cancer worldwide, with the second highest 
mortality rate. Its poor mortality is linked to delayed presentation. There is a drive towards non-invasive 
biomarker screening and monitoring of many different types of cancer, although with limited success so far. 
We aimed to determine if any genes from a 32-gene panel could be used to determine GC prognosis.
Methods: We carried out a retrospective study on the expression of 32 genes, selected for their proven or 
potential links to GC, on historic formalin fixed paraffin-embedded (FFPE) GC specimens from our unit. 
Gene expression was measured using quantitative nuclease protection assays (qNPA) technology. Following 
statistical analysis of the results, immunohistochemical staining for eight genes, both discriminating and non-
discriminating, was conducted in seven age and sex matched non-metastatic: metastatic GC pairings. The 
stained samples were reviewed by two blinded consultant histopathologists. 
Results: Multivariate Cox analysis of the gene expression data revealed metastatic status, age, sex and five genes 
appeared to influence GC survival. Genes negatively influencing survival included BCAS1, P53 and HSP90AA1 
(relative risks 2.20, 3.73 and 7.53 respectively). Genes conveying survival benefit included CASP3 and TERT 
(relative risks 0.10 and 0.24 respectively). Immunohistochemical staining of seven age and sex matched non-
metastatic: metastatic pairs revealed no association between gene expression and protein expression. 
Conclusions: Our study found several genes whose expression may affect GC prognosis. However, 
immunohistochemical analysis revealed no association between gene expression and protein expression. It 
remains to be determined whether gene expression or protein expression are reliable means of assessing GC 
prognosis. 
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diffuse type. Several aetiological factors in the development 
of GC have been identified, including Helicobacter pylori 
infection, high salt and low fruit and vegetable diets, 
smoking, obesity, radiation exposure, pernicious anaemia, 
blood group A and family history (1). 
The presentation of GC is often delayed due to the non-
specific nature of symptoms. Delayed presentation often 
results in more advanced disease at diagnosis, meaning 
curative surgery is not possible and palliative treatment 
becomes the treatment of choice (3,4). This unsurprisingly 
leads to an overall poor prognosis for GC. Five-year 
survival rates have been quoted ranging from 36–47% in 
large Western trials (5), with other sources quoting as low 
as 20% overall and 5% for metastatic disease (6). 
Given these poor outcomes there is a drive for the earlier 
biomarker detection of GC, when the disease is at a more 
treatable stage. Carcinoembryonic antigen, carbohydrate 
antigen (CA) 19-9 and CA72-4 are perhaps the best-known 
tumour markers, although they are not ideal due to their 
relatively low sensitivity and specificity (20–30%) (7). Many 
genes have been identified as having potential roles in the 
determination of prognosis for GC and as potential or 
actual targets for chemotherapy. 
Perhaps the best understood biomarkers for GC 
prognosis are E-cadherin and c-erbB2. E-Cadherin 
germline mutations were shown to result in depleted 
E-cadherin levels and the subsequent development of 
aggressive, poorly differentiated GC (8). c-erbB2 mutations 
meanwhile were shown to promote tumour invasion and 
metastasis, thus suggesting a potential for targeted therapy 
aimed at controlling disease spread (9). 
A review by Kanda and Kodera has summarised recent 
research into potential GC biomarkers (7). They identified 
found multiple genes with altered expression or processing 
which have a role in early detection, recurrence (c-erbB2), 
predicting survival and predicting treatment response. 
Those overexpressed genes linked with predicting survival 
included cell surface proteins (B7-H4), adhesion factors 
(DPYSL3), transcription factors (MYCL1, YBX1), matrix 
proteins (SERPINA1) and cell cycle regulators (S100A6, 
CCND1). Down regulated genes which appeared to help 
predict survival included extracellular matrix proteins 
(ITIH5), tight junction assembly (JAMA), with SEMA3A 
and STUB1 implicated in tumour proliferation. They 
further identified genes with aberrant DNA methylation 
which can affect survival. These included phosphorylation 
inhibitor (PEBP1), cell growth suppressors (RASSF5A), 
cytokine suppressors (SOCS4), transcription factors (SOX17, 
TCF21) and gastric mucosa protection (TFF1). Interestingly, 
studies which looked at both gene expression and protein 
expression, used reverse transcription-polymerase chain 
reaction (RT-PCR) to amplify up mRNA levels for gene 
expression analysis. The authors of the review concluded 
that despite these many genes being identified that there is 
still a long way to go before any potential clinical use due to 
the high degree of individual variation between patients and 
there is still a lack of large scale studies. 
Colorectal cancer and B cell lymphomas have previously 
successfully had a panel of genes identified which can 
aid in the prognosis of the two diseases (10,11). This has 
been achieved by tissue analysis with microarray analysis 
[specifically quantitative nuclease protection assays (qNPA)]. 
NPA technology analyses mRNA levels without the need 
for initial extraction followed by RT-PCR, which allows 
the use of formalin fixed paraffin-embedded (FFPE) tissues. 
The benefit of this assay over RT-PCR is that it allows the 
simultaneous processing of large sample numbers with only 
small amounts of preserved tissue—essential where only 
biopsies of tumour tissue may be available. It also reduces 
the amount of pre-processing that would be necessary for 
RT-PCR analysis. 
Using this microarray technique, we studied the 
expression of 32 candidate genes in historical GC specimens 
and then looked to verify the expression levels using 
immunohistochemistry (IHC) analysis. These 32 genes were 
identified as having potential prognostic interest or value 
in GC. Our aim was to determine if any yet unidentified 
genes could be used as an aid in the assessment of prognosis 
for GC patients. To our knowledge, although previous 
studies have used RT-PCR to assess gene expression and 
then followed this with immunohistochemical analysis, this 
is the first study to utilise microarray technology to look at 
gene expression in GC and then attempt verification using 
immunohistochemistry. 
Methods
Patients
The University Hospital Coventry and Warwickshire 
(UHCW) pathology database was searched for all gastric 
adenocarcinomas diagnosed between April 2005 and 
September 2006. Demographic data was recorded detailing 
the patients’ age, sex, tumour stage and survival. As the 
records were historical there was little data available on 
smoking status etc. Fifty-seven patients were identified 
305Journal of Gastrointestinal Oncology, Vol 9, No 2 April 2018 
© Journal of Gastrointestinal Oncology. All rights reserved.   J Gastrointest Oncol 2018;9(2):303-310jgo.amegroups.com
and divided into two groups, those with metastatic disease 
(n=22), those with no metastatic disease (n=35), who went 
on to have either curative intent surgery, or who did not 
have surgery for various reasons, including frailty and or 
mortality or morbidity. Ethical approval was obtained from 
the Birmingham Research Ethics Committee, the West 
Midlands (10/H1210/9).
Gene selection
We selected a panel of 32 genes, some of which have 
been previously reported as having prognostic value in 
GC (e.g., E-cadherin), others were selected as they have 
been shown to have prognostic value in other cancer 
(BCAS1). Housekeeping genes were incorporated by High 
Throughput Genomics (HTG) (Inc., Tucson, AZ, USA) 
genomics (GAPDH, PPIA, RPLPO, ACTB) and were used as 
a reference set and enabled normalization of data between 
samples. The full list of genes is shown in Table 1.
Preparation of FFPE tissue specimens
Historical tissue specimens were selected and recovered 
from the tissue archives. The specimens had previously 
been fixed in FFPE. 
Sample preparation for ArrayPlate assay
FFPE sections were prepared and analysed using qNPA 
ArrayPlates by High Throughput Genomics,  Inc. 
(Tucson, AZ, USA). The FFPE specimens were cut to 
5-mm thickness and placed into 75 mL HTG lysis buffer 
(25 mL/section), vortexed briefly, then heated at 95 ℃ for 
10 min, re-vortexed briefly, and finally frozen at −70 ℃ 
until analysis. One cut of 5-mm-thick tissue was used per 
well on the ArrayPlate, but the HTG lysis buffer containing 
the multiple sections was used for the three ArrayPlate 
wells required to measure all the genes in the assay, or for 
replication in the validation assays. Roberts et al. found in 
their work that unless the FFPE tissue was thinly cut then 
poor results were achieved (10). 
ArrayPlate assay
To confirm the expression levels of the target genes, qNPA 
was performed on RNA extracted from FFPE GC sections. 
The DNA probes for the genes of interest were incubated 
with the processed tumour samples forming probe-mRNA 
complexes. Unhybridized probes were then digested by 
S1 nuclease. Alkaline hydrolysis was then used to destroy 
the mRNA in the duplexes leaving only intact probes 
at concentrations reflective of the amounts of original 
mRNA present. The processed samples were transferred to 
programmed (linker-modified) ArrayPlates. The ArrayPlates 
were then exposed to linker oligonucleotides to bind allow 
specific binding to the probes. The ArrayPlates were then 
washed with detection oligonucleotides which bound 
to the linker molecules. The detection oligonucleotides 
contained horseradish peroxidase, which upon addition 
of a chemiluminescent peroxidase substrate led to each 
array element giving off a light signal in proportion to the 
amount of sample probe bound to the well at that position. 
The signals from the ArrayPlates were viewed from the 
bottom with an OMIX HD imager. The digital images 
of ArrayPlates were analyzed by ArrayPlate Fit (v.3.31a) 
software. The resulting data were analyzed by ArrayPlate 
Crunch software to normalize signals with housekeeping 
genes and to calculate individual gene expression levels. 
The ArrayPlate assay has been more extensively described 
previously by Roberts et al. (10).
Immunohistochemistry
Once gene expression levels  were known for the 
various genes in the GC FFPE specimens, Standard 
immunohistochemistry techniques were performed on 
the original FFPE tissue using commercially purchased 
antibodies against the proteins encoded by the various 
elected genes. The FFPE specimens were sliced, washed, 
the primary antibody annealed to them, then rewashed 
and the secondary antibody applied and rewashed. The 
stained specimens were then reviewed by two consultant 
pathologists, with the second blinded, to assess the levels of 
protein expression for the various identified genes. 
Statistical methods
We used a multivariate Cox proportional hazard model. It 
was fit with stepwise factor selection to determine a set of 
most relevant factors for the length of survival. Bayesian 
information criterion (BIC) was used to select the factors 
ensuring accurate fit while punishing against the inclusion 
of unnecessary many variables. Apart from the (continuous) 
gene expression variables, categorical variables for 
metastatic groups, palliative status, as well as basic patient 
information (age, sex) was included in the set up.
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Table 1 List of 32 candidate genes and pathways
Pathway/gene OMIM
Wnt
Wnt10A 606268
Wnt1 164820
Regulated by microRNAs
HOXD10 142984
Tropomysin1 191010
N-RAS 164790
K-RAS 190070
Phosphatidylinositol 3 kinase
Subunit 1 171833
Caspases
Caspase 3 600636
BCL2 151430
Ghrelin 605353
APC 611731
COX2 600262
AIB 602968
EGFR 131550
Trefoil factors
Trefoil factor 1 113710
Heat shock proteins
Hsp90 140571
Hsp60 118190
Beta catenin 116806
Telomerase and associated 
proteins
Telomerase 187270
TEP1 601686
TIN2 604319
TERT 187270
TERC 602322
PINX1 606505
MAD/Myc pathway
cMyc 190080
Max 154950
Mad3 609450
Table 1 (continued)
Table 1 (continued)
Pathway/gene OMIM
Notch
Notch1 190198
Notch2 600275
Cell cycle
TP53 191170
P16 600160
DNA repair
MLH1 120436
MSH2 609309
PMS1 600258
E-cadherin 192090
EGFR, epidermal growth factor receptor; OMIM, Online Mendelian 
Inheritance in Man.
Two main challenges from the data set had to be taken 
into account. Firstly, the number of patients is small 
compared to the number of factors considered. Rather than 
interpreting significance levels in the traditional univariate 
sense we understand them as ranks providing a list of 
most relevant factors. Secondly, gene measurements were 
taken from different types of samples (only tumour, only 
biopsy, both). However, there is validity within patients 
and justifying that both sample types are meaningful. For 
the analysis, biopsy samples were used whenever available. 
Analysis was performed with open access software R and 
packages survival and MASS.
Results
The demographic data of the GC patients are shown in 
Table 2. The mean age was 72 years [standard deviation 
(SD): 11.5] and 39 (68%) were male. The mean age of the 
non-metastatic group was 71 (SD: 13) and the mean age of 
the metastatic group was 73.5 (SD: 9). The mean survival 
time of non-metastatic was 23.6 months (SD: 26.4) and the 
mean survival of metastatic was 7.0 months (SD: 10.0). As 
expected the mean survival time was highly dependent on 
metastatic status.
Gene expression
Stepwise model selection using multivariate Cox PH 
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model including metastatic status, age, sex and 32 gene 
expression values returned an optimal model which showed 
that metastatic status, age, sex and five genes appeared 
to influence the survival in GC. Genes which appears 
to negatively influence survival (i.e., shorten) include; 
BCAS1, P53 and HSP90AA1 with relative risks [exp(coef)] 
of 2.20, 3.73 and 7.53 respectively. Genes which appeared 
to convey a survival benefit on patients included CASP3 
and to a lesser extent, TERT with relative risks of 0.10 and 
0.24 respectively. A list of these genes, the Cox PH survival 
coefficients and p values can be found in Table 3. 
Immunohistochemical analysis
IHC analysis of the GC tissue specimens was carried out as 
described above. Genes which were stained for included the 
discriminating genes P53, HSP90AA1, CASP3 and BCAS1, 
and the non-discriminating genes NOTCH1, MLH, PSM1 
and HOXD10 as controls. Nine non-metastatic patients (i.e., 
had curative intent surgery) and nine metastatic patients 
had their tissue samples subjected to IHC assessment as 
described in the methods. The resulting stained specimens 
were analysed by two Consultant pathologists (the second 
blinded) and scored for their expression of levels. The two 
groups of patients were age and sex matched to each other 
for analysis. 
The CASP3 staining failed and there was insufficient 
tissue on several samples such that repeat attempts at 
staining would not have allowed for meaningful comparison. 
Similarly, two of the patients’ samples were unsuitable for 
analysis after processing and staining. Which left seven age 
sex matched patient specimens for comparison (Table 4).
The results of the IHC staining did not verify the results 
of the microarray analysis. The expression levels of proteins 
were either the same in non-metastatic and metastatic 
specimens or the expression was reduced in the metastatic 
specimens for genes which carried a negative survival 
benefit in the microarray analysis. In the case of HSP90AA1 
the expression levels were less in the metastatic specimen 
in three out of seven pairs, the same in one out of seven 
pairs and more in three out seven pairs. TP53 had lower 
levels of expression metastatic specimens compared to non-
metastatic specimens in one out of seven pairs, higher levels 
similar levels in two out seven pairs and equal levels of 
expression in four out of seven pairs. BCAS1 showed similar 
levels of expression in three out of seven pairs, reduced 
expression in metastatic specimens in two out of seven pairs 
and increased expression in metastatic specimens for two 
out of seven pairs. 
The non-discriminating genes, which showed no effect 
on survival, gave a very similar mixed pattern of similar, 
reduced and increased expression in metastatic specimens. 
The pathologist interpretation of the IHC staining was in 
absolute or close agreement in 90% of stained samples. The 
remaining samples where there was a larger discrepancy did 
not affect the pattern of IHC staining described above. 
Discussion
Our study sought to determine whether any yet unidentified 
genes could be identified to assist with determining 
prognosis in GC. This expands on previous studies which 
have identified many genes which appear to affect the 
survival of GC patients. Statistical analysis of our gene 
expression data, based on qNPA technology, identified 
that prognosis was, unsurprisingly, negatively affected 
by increasing age, male sex and metastatic disease. It also 
identified five genes (which have statistically significant 
P values) which affect GC prognosis: three negatively 
i.e., poorer survival (BCAS1, P53 and HSP90AA1) and 
Table 2 Gastric cancer patient demographic data
Demographics
Non-metastatic 
(n=35)
Metastatic 
(n=22)
Age (years) [SD] 71 [13] 73.5 [9]
Sex (M:F) 24:11 15:7
Survival (months) [SD] 23.6 [26.4] 7.0 [10.0]
M, male; F, female; SD, standard deviation. 
Table 3 Survival co-efficient and P values from multivariate Cox 
analysis of gene expression
Gene 
Relative risk [exp(coef)] 
(95% CI)
P (>|z|)
Stage 2.70 (1.08–6.79) 0.034
Palliative 4.69 (1.86–11.82) 0.0010
TERT 0.24 (0.13–0.46) 0.00000092
HOXD10 0.98 (0.97–0.99) 0.0032
BCAS1 2.20 (1.50–3.24) 0.0000062
CASP3 0.10 (0.03–0.32) 0.00015
TP53 3.73 (1.58–8.81) 0.0027
HSP90AA1 7.53 (2.94–19.32) 0.0000026
308 McFarlane et al. Prognostic genes for GC
© Journal of Gastrointestinal Oncology. All rights reserved.   J Gastrointest Oncol 2018;9(2):303-310jgo.amegroups.com
two positively i.e., better survival (CASP3 and TERT). 
Four of these discriminating genes were analysed by IHC 
techniques in seven non-metastatic patients who had 
gastric resections with curative intent, and seven age and 
sex matched metastatic patients. The IHC results showed 
that the protein expression levels within the tissue samples 
did not correspond with the mRNA gene expression levels 
determined in the NPA microassays. This appeared to be 
the case not just for the discriminating genes that were 
chosen but also for the non-discriminating genes (NOTCH1, 
HOXD10, PSM1 and MLH). 
Whilst our study appears to have identified several 
genes which at an mRNA levels may affect the prognosis 
of GC, the protein expression of these genes appears to 
be uncoupled from the gene expression. The precise point 
of the protein expression pathway (i.e., translation, post 
translational modification) at which this uncoupling process 
occurs could not be determined from this experiment. The 
mechanisms behind why this uncoupling has occurred 
will require further study but they may represent part of 
the more generalised cell malfunction which occurs with 
carcinogenesis. 
Interestingly this is not the first study to demonstrate 
that protein expression appears to be disparate from gene 
expression in cancerous cells. Dickson et al. demonstrated 
that JAG1 gene and protein expression in breast cancer 
is associated with poorer prognosis, however, when they 
carried out IHC studies they determined that there was only 
a 65% agreement between mRNA and protein levels (12). 
Stark et al. studied protein and mRNA levels in primary 
breast cancer and in brain metastases. They demonstrated 
that whilst BCL-2 mRNA and protein expression levels 
were in good agreement (and lower in the brain metastases), 
P53 mRNA levels were significantly lower in the metastases 
than the primary tumours but the protein levels were only 
slightly lower in the metastases (not to significant levels). 
Finally, they found that BAX mRNA and protein levels 
were completely discordant with the metastases showing 
lower levels of mRNA expression than the primary tumour, 
but higher levels of protein expression (13). Sarro et al. 
studied CD20 levels in chronic lymphocytic leukemia 
(CLL) and demonstrated that CD20 mRNA levels where 
normal or near normal compared to healthy controls whilst 
the CD20 protein levels were reduced by ~60% in CLL 
cells compared to healthy controls (14). Finally, it has been 
demonstrated in prostate cancer that mRNA and protein 
Table 4 Immunohistochemical analysis of age:sex matched pairs of metastatic and non-metastatic gastric cancer patients for discriminating and 
non-discriminating genes
Patient 
pair
Metastatic status 
(non-met; met)
Gene/protein (discriminating/non-discriminating)
HSP90AA1 (D) TP53 (D) BCAS1 (D) CASP3 (D) HOXD10 (N) MLH (N) NOTCH1 (N) PSM1 (N)
1 Non-met 2+ cyto 2+ nuc 2+ cyto Failed 1+ cyto 1+ nuc Negative Negative
Metastatic 2+ cyto Negative Negative Failed 1+ cyto 1+ nuc Negative 1+ cyto
2 Non-met 2+ cyto Negative Negative Failed 1+ cyto Negative Negative 1+ cyto
Metastatic 3+ cyto 3+ nuc Negative Failed 2+ cyto Negative Negative 1+ cyto
3 Non-met 2+ cytp Negative Negative Failed 1+ cyto 1+ nuc Negative 1+ cyto
Metastatic 3+ cyto 3+ nuc Negative Failed 3+ cyto Negative 1+ mem 3+ cyto
4 Non-met 2+ cyto 3+ nuc Negative Failed Negative Negative 2+ mem Negative
Metastatic Negative 3+ nuc 1+ cyto Failed 3+ cyto 2+ nuc Negative Negative
5 Non-met 1+ cyto Negative Negative Failed Negative Negative Negative Negative
Metastatic 2+ cyto Negative 1+ cyto Failed 2+ cyto 2+ nuc Negative 3+ cyto
6 Non-met 3+ cyto Negative Negative Failed 2+ cyto Negative Negative Negative
Metastatic 2+ cyto Negative Negative Failed 1+ cyto Negative 1+ mem Negative
7 Non-met 3+ cyto Negative 1+ cyto Failed 1+ cyto Negative Negative 1+ cyto
Metastatic 1+ cyto Negative Negative Failed negative 2+ nuc Negative 1+ cyto
cyto, cytoplasmic; nuc, nuclear; mem, membrane.
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levels of MMP-2, MMP-9 and TIMP-1 show no significant 
correlation (15). 
The previous studies using microarray technology 
and immunohistochemistry to assess gene expression in 
colorectal cancer and B cell lymphoma found that protein 
expression levels did correlate with the microarray findings 
(11,12). This could suggest that GC has a different cellular 
behaviour to the other cancers previously studied using this 
method, or that the genes we selected were not fundamental 
to the GC pathogenesis process. 
Conclusions
Our study utilised microarray technology to try to identify 
potential gene candidates to aid in determining the 
prognosis of GC. Biopsy specimens were used in most cases 
to make a prognostic assignment possible using endoscopic 
biopsies take at initial cancer diagnosis. We identified five 
potential genes utilising the microarray technique on FFPE 
specimens. We then undertook subsequent IHC analysis of 
the identified genes. This is to our knowledge the first time 
this has been done on GC specimens. The IHC analysis did 
not show concordance in the mRNA levels between either 
the discriminating genes or the control genes we selected. 
This suggests that there is a disconnection between the 
gene expression and protein expression of GC cells. 
Given this finding it is too early to suggest whether these 
identified genes could have roles as prognostic biomarkers, 
or as predictors of response to therapy. Further, larger 
studies, including a verification cohort would be necessary 
to determine if the mRNA and protein expression findings 
of our study are a true reflection of the cellular processes 
which occur during GC carcinogenesis. The quest for a 
biomarker to aid in the diagnosis and prognosis of GC 
continues. 
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